Ken Blount
Senior Vice President, Head of Microbiome Clinical & Product Development Ferring Pharmaceuticals
Ken Blount is Senior Vice President, Head of Microbiome Clinical and Product Development at Ferring Pharmaceuticals and a recognized leader in microbiome therapeutic development. With extensive experience spanning discovery, clinical development, regulatory strategy, and commercialization, he has helped advance multiple microbiome-based therapies from early research through regulatory approval and launch. Throughout his career, Ken has led CMC development, clinical trial programs, and evidence-generation initiatives supporting both medical and commercial success. He has played a pivotal role in shaping the microbiome therapeutics industry, including chairing the Microbiome Therapeutics Innovation Group and contributing to key regulatory and industry advisory efforts.
Seminars
Pharma skepticism towards microbiome therapeutics, driven by past clinical failures and difficulty distinguishing robust science, has delayed partnership engagement until Phase II data. This workshop outlines how to package mechanistic insight and early clinical evidence to meet pharma expectations and unlock earlier, higher-quality partnering conversations.
Workshop highlights:
- Structuring differentiated mechanism-of-action narratives using immune, metabolic, and microbial pathways to position programs in language that resonates with pharma decision-makers.
- Aligning early clinical study design with pharma-preferred endpoints and indications to generate signals that support future regulatory and commercial success
- Positioning Phase I, translational, and biomarker datasets strategically to maintain engagement and credibility despite limited late-stage outcome data availability
- Demonstrating scientific validation across heterogeneous microbiome approaches to clearly separate high-quality programs from lower-confidence competitors in crowded pipelines
- Examining mechanism of action data from microbiome therapeutic programs to build evidence-based narratives that strengthen regulatory and pharma partnership credibility
- Leveraging pharmacokinetic and engraftment data from clinical trials to deepen process understanding and demonstrate reproducible therapeutic activity in target indications
- Applying mechanistic insights from donor-derived and defined consortium programs to inform next-generation microbiome therapeutic development strategies
